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Abstract
Background: Aberrant promoter hypermethylation of cancer-associated genes occurs frequently
during carcinogenesis and may serve as a cancer biomarker. In this study we aimed at defining a
quantitative gene promoter methylation panel that might identify the most prevalent types of renal
cell tumors.
Methods: A panel of 18 gene promoters was assessed by quantitative methylation-specific PCR
(QMSP) in 85 primarily resected renal tumors representing the four major histologic subtypes (52
clear cell (ccRCC), 13 papillary (pRCC), 10 chromophobe (chRCC), and 10 oncocytomas) and 62
paired normal tissue samples. After genomic DNA isolation and sodium bisulfite modification,
methylation levels were determined and correlated with standard clinicopathological parameters.
Results: Significant differences in methylation levels among the four subtypes of renal tumors were
found for CDH1  (p  = 0.0007), PTGS2  (p  = 0.002), and RASSF1A  (p  = 0.0001). CDH1
hypermethylation levels were significantly higher in ccRCC compared to chRCC and oncocytoma
(p = 0.00016 and p = 0.0034, respectively), whereas PTGS2 methylation levels were significantly
higher in ccRCC compared to pRCC (p = 0.004). RASSF1A methylation levels were significantly
higher in pRCC than in normal tissue (p = 0.035). In pRCC, CDH1 and RASSF1A methylation levels
were inversely correlated with tumor stage (p = 0.031) and nuclear grade (p = 0.022), respectively.
Conclusion: The major subtypes of renal epithelial neoplasms display differential aberrant CDH1,
PTGS2, and RASSF1A promoter methylation levels. This gene panel might contribute to a more
accurate discrimination among common renal tumors, improving preoperative assessment and
therapeutic decision-making in patients harboring suspicious renal masses.
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Background
Cancer is currently a major cause of morbidity and mor-
tality in Western World, only surpassed by cardiovascular
diseases [1]. Kidney cancer accounts for approximately
three percent of all solid neoplasms and its incidence
appears to be rising [2]. Overall, it is estimated that 208
480 new cases of kidney cancer were diagnosed world-
wide in 2002, with a total of 101 895 deaths [1]. In the
USA, the adjusted incidence and mortality of this disease
were approximately two times higher in males than in
females, standing as the 7th leading malignant condition
among men and the 12th among women [2]. In 2006, 38
890 new cases and 12 840 deaths are predicted to occur in
the USA [2], whereas in Europe there were 85 719 cases
and 45 270 deaths in 2002 [1]. The vast majority of renal
cell tumors are sporadic as only 2% of cases are associated
with inherited syndromes [3].
Renal cell tumors account for about 85 percent of all adult
renal neoplasms, comprising a heterogeneous class of epi-
thelial tumors that range in biological potential from
entirely benign to highly malignant [4]. Common his-
topathologic subtypes include clear cell renal cell carci-
noma (ccRCC, ~75% of surgically removed renal cell
tumors), papillary RCC (pRCC, ~10%), chromophobe
RCC (chRCC, ~5%), and oncocytoma (~5%) [5]. Most
renal cell tumors are clinically silent in their earlier stages
and 20–30% are diagnosed when metastatic spread has
already occurred [6]. However, the widespread use of ima-
giologic testing (mainly ultrasonography) has increased
the detection of renal masses, prompting new pre-opera-
tive diagnostic challenges as histological diagnosis using
needle biopsy material meets with important limitations,
hampering an accurate categorization [7]. Thus, there is a
need for the development of new strategies both for early
detection and differential diagnosis of renal cell tumors.
Epigenetic alterations and gene promoter hypermethyla-
tion in particular, provide an emerging class of cancer
biomarkers, holding the promise of sensitive and accurate
disease detection even at the earliest stages [8]. The power
of epigenetic markers for molecular detection of the most
common urological malignancy (i.e., prostate cancer) has
been demonstrated in previous studies from our research
team and others [9-15]. Some previous studies attempted
a characterization of the RCC methylome, but either they
did not comprise some the most frequent histological
subtypes [16-18], did not use the more sensitive and spe-
cific quantitative assays [18-20], or have examined only a
limited number of primary RCC [16-18]. Thus, it might be
stated that the discovery of methylation markers in RCC
provides an attractive and still largely unexplored field for
biomedical research.
In the present study we aimed at the definition of a gene
promoter methylation panel that might discriminate
among most prevalent types of epithelial kidney tumors,
including the most common RCC subtypes and oncocy-
toma, which may serve as ancillary tools for diagnosis and
prognosis assessment. For that purpose, the promoter
region of 18 cancer-related genes (which were chosen
based on their established relevance to various human
cancers and, specifically, RCC), was surveyed for CpG
methylation using quantitative real-time PCR in a rela-
tively large series of kidney tumors and morphologically
normal tissue. In addition, methylation data was corre-
lated with the relevant clinicopathologic data.
Methods
Patients, sample collection, and DNA extraction
Eighty-five patients with ccRCC, pRCC, chRCC, or onco-
cytoma, consecutively diagnosed and treated with partial
or radical nephrectomy at the Portuguese Oncology Insti-
tute – Porto, Portugal, between April 2001 and June 2003,
were selected for this study after written informed consent
was obtained. Samples of tumor and morphologically
normal tissue distant to the primary tumor (when availa-
ble) were immediately obtained after surgical resection,
fresh-frozen, and stored at -80°C for further analysis.
Additional samples were taken for routine pathological
evaluation, after formalin-fixation and paraffin embed-
ding. The correspondent hematoxylin-eosin-stained sec-
tions were examined by the same pathologist (RH) to
determine the tumor type [4], nuclear grade [21], and
pathological stage [4]. Frozen sections (five-micron thick)
were cut and stained for the identification of the areas of
tumor and morphologically normal tissue. Then, the tis-
sue block was trimmed to maximize the yield of target
cells (>70% of target cells). Subsequently, approximately
fifty 12 μm thick sections were cut and every 5th section
was stained to ensure a uniform percentage of target cells
and to exclude contamination of normal tissue samples
with neoplastic cells. Genomic DNA was extracted from
tumor and normal tissue using a standard technique com-
prising overnight digestion with proteinase K (20 mg/mL)
in the presence of 10% SDS at 55°C, followed by phenol-
chloroform extraction and precipitation with 100% etha-
nol [22].
Relevant clinical data was collected from patient's clinical
records. These studies were approved by the institutional
review board (IRB) of the Portuguese Oncology Institute
– Porto.
Bisulfite treatment and QMSP
Sodium bisulfite conversion of unmethylated (but not
methylated) cytosine residues to uracil was performed as
previously described [23]. Briefly, four μg of genomic
DNA were denatured in 0.3 M NaOH for 20 min at 50°C.BMC Cancer 2007, 7:133 http://www.biomedcentral.com/1471-2407/7/133
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The denatured DNA was diluted in 450 μl of a freshly pre-
pared solution of 125 mM hydroquinone and 2.5 M
sodium bisulfite and was incubated for 3 h at 70°C. After
incubation, modified DNA samples were desalted and
purified through a column (Wizard DNA Clean-Up Sys-
tem; Promega, Madison, WI), treated again with sodium
hydroxide for 10 min at room temperature, precipitated
with 100% ethanol, resuspended in 240 μl of water, and
stored at -80°C.
The chemically modified DNA was then used as a tem-
plate for quantitative methylation-specific PCR [24]. In
brief, primers and probes were designed to specifically
amplify fully methylated bisulfite-converted complemen-
tary sequences of the promoter of interest. The 18 cancer-
related genes used in this renal cancer detection panel
were genes involved in cell communication and signal
transduction (APC [25], ARHI [26], CDH1 [25], CTNNB1
[25],  SFN  [27]); cell cycle regulation (ARF/p14  [25],
CDKN2A/p16  [28],  RASSF1A  [27]); metabolism and
energy pathways (GSTP1 [9], MDR1 [29], MTHFR [25],
PTGS2 [25], TIMP3 [25]); and regulation of nucleic acid
metabolism (ESR1 [25], ESR2 [26], FHIT, MGMT [28],
RARβ2). The primers and probe sequences studied have
all been reported previously and can be found in the pub-
lications referenced after each gene. The primers and
probe sequences used for the FHIT [GenBank: U76263]
and RARβ2 [GenBank: NM_000965] were the following,
respectively: sense, 5'-GGG CGC GGG TTT GGG TTT TTA
C-3'; antisense, 5'-GAA ACA AAA ACC CAC CGC CCC G-
3'; and probe, 6FAM-5'-AAC GAC GCC GAC CCC ACT
AAA CTC C-3'-TAMRA and sense, 5'-GGG ATT AGA ATT
TTT TAT GCG AGT TGT-3'; antisense, 5'-TAC CCC GAC
GAT ACC CAA AC-3'; and probe, 6FAM-5'-TGT CGA GAA
CGC GAG CGA TTC G-3'-TAMRA. To normalize for DNA
input in each sample, a reference gene (β-actin [25]) was
used.
Fluorescence based real-time PCR assays were carried out
in a reaction volume of 20 μL, consisting of 16.6 mM
ammonium sulfate; 67 mM trizma preset; 6.7 mM MgCl2
(2.5 mM for p16); 10 mM mercaptoethanol; 0.1% DMSO;
200 μM each of dATP, dCTP, dGTP, and dTTP; 600 nM of
each primer; 0.4 μL of Rox dye; 200 nM of probe; 1 unit
of platinum Taq polymerase (Invitrogen, Carlsbad, CA),
and 2 μl of bisulfite-modified DNA as a template. PCR
was performed in separate wells for each primer/probe set
and each sample was run in triplicate. Additionally, mul-
tiple water blanks were used per plate, as a control for con-
tamination (negative control). Leukocyte DNA collected
from healthy individuals was methylated in vitro with
excess SssI CpG methylase (New England Biolabs Inc.,
Beverly, MA) to generate completely methylated DNA at
all CpGs (positive control), and serial dilutions of this
DNA after bisulfite conversion were used for constructing
the calibration curve to quantify the amount of fully
methylated alleles in each reaction. All amplifications
were carried out in 96-well plates on an 7000 Sequence
Detection System (Applied Biosystems, Foster City, C.A.),
at 95°C for 2 min followed by 50 cycles of 95°C for 15 s,
and 60°C for 1 min. For the SFN gene promoter QMSP
assay, the reaction was carried out under the same condi-
tions, except for the annealing temperature (62°C).
To determine the relative levels of methylated promoter
DNA in each sample, the values obtained by QMSP anal-
ysis (mean quantity) for each target gene were divided by
the respective values of the internal reference gene
(ACTB). The ratio thus generated, which constitutes an
index of the percentage of input copies of DNA that are
fully methylated at the primer- and probe-binding sites,
was then multiplied by 1000 for easier tabulation (meth-
ylation level = target gene/reference gene × 1000).
Statistical analysis
The frequency of methylated samples, as well as the
median and interquartile range of the methylation level
for each target gene was determined. Values were analyzed
using non-parametric tests, i.e., the Kruskal-Wallis
ANOVA, followed by the Mann-Whitney U test when
appropriate. For multiple comparisons the Bonferroni
method was used to adjust the P values. Results were con-
sidered statistically significant at the two-sided 5% signif-
icance level. Statistical analyses were carried out using a
computer-assisted program (Statistica for Windows, ver-
sion 6.0, StatSoft, Tulsa, OK).
Results
Clinical and pathological data
Relevant clinical and pathological characteristics of the
patients included in this study are summarized in Table 1.
As expected, males were more frequently diagnosed with
renal cell tumor than females and ccRCC was the most fre-
quent subtype. Most cases of RCC were confined to the
organ and were classified as nuclear grade two or three.
QMSP in renal cell tumors and normal renal tissue
Using a QMSP assay, we examined the hypermethylation
status of a panel of 18 cancer-related genes involved in
several cancer pathways. The frequency and distribution
of promoter methylation at each locus included in this
panel are listed in Tables 2 and 3, respectively.
Promoter hypermethylation in at least one of the target
genes was detected in all analyzed tissue samples, either
tumor or normal renal tissue. CTNNB1 and CDKN2A pro-
moter methylation was not found in any tissue sample.
On the contrary, ARHI, MTHFR, and SFN promoter meth-
ylation was detectable in all tissue samples. Statistical
analyses of distribution of methylation levels among theBMC Cancer 2007, 7:133 http://www.biomedcentral.com/1471-2407/7/133
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four tumor types disclosed significant differences for three
genes, i.e., CDH1, PTGS2, and RASSF1A. Pair-wise com-
parisons are shown and graphically illustrated in Fig. 1.
Overall, chRCC and oncocytomas displayed a similar
methylation profile, with low methylation levels in the
three promoters. ccRCC are characterized by higher
PTGS2 methylation levels, sharing with pRCC significant
methylation at the CDH1 promoter. However, RASSF1A






Age, yr, median (range) 61 (36–86)
Histologic subtype, n (%)
Clear cell RCC 52 (61.2)
Papillary RCC 13 (15.2)
Chromophobe RCC 10 (11.8)
Oncocytoma 10 (11.8)










RCC, renal cell carcinoma, * only includes RCC cases
Table 2: Percentage and frequency of methylation [% (n)] of cancer-related genes in subtypes of renal cell carcinoma (RCC), 
oncocytoma, and morphologically normal renal tissue (NRT)
Clear cell RCC Papillary RCC Chromophobe RCC Oncocytoma NRT
Gene Gene loci % (n = 52) % (n = 13) % (n = 10) % (n = 10) % (n = 62)
APC 5q21-q22 19.2 (10) 23.1 (3) 0 (0) 0 (0) 8.1 (5)
ARHI 1p31 100 (52) 100 (13) 100 (10) 100 (10) 100 (62)
CDH1 16q22.1 82.7 (43) 69.2 (9) 20 (2) 30 (3) 87.1 (54)
CTNNB1 3p21 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
SFN 22q12.3 100 (52) 100 (13) 100 (10) 100 (10) 100 (62)
ARF/p14 9p21 9.6 (5) 7.7 (1) 10 (1) 20 (2) 27.4 (17)
CDKN2A/p16 9p21 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
RASSF1A 3p21.3 80.8 (42) 100 (13) 40 (4) 90 (9) 100 (62)
GSTP1 11q13 5.8 (3) 15.4 (2) 0 (0) 0 (0) 0 (0)
MDR1 7q21.1 86.5 (45) 84.6 (11) 80 (8) 90 (9) 96.8 (60)
MTHFR 1p36.3 100 (52) 100 (13) 100 (10) 100 (10) 100 (62)
PTGS2 1q25.2-q25.3 96.1 (50) 92.3 (12) 90 (9) 90 (9) 100 (62)
TIMP3 1p36.11 19.2 (10) 23.1 (3) 0 (0) 0 (0) 24.2 (15)
ESR1 6q25.1 67.3 (35) 76.9 (10) 60 (6) 80 (8) 77.4 (48)
ESR2 14q23.2 55.8 (29) 46.1 (6) 50 (5) 30 (3) 43.5 (27)
FHIT 3p14.2 51.9 (27) 53.8 (7) 50 (5) 50 (5) 69.3 (43)
MGMT 10q26 1.9 (1) 0 (0) 0 (0) 0 (0) 11.3 (7)
RARβ2 3p24 1.9 (1) 0 (0) 0 (0) 0 (0) 0 (0)BMC Cancer 2007, 7:133 http://www.biomedcentral.com/1471-2407/7/133
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methylation stands as the most distinctive feature of
pRCC in this epigenetic profile.
The 62 morphologically normal tissue samples matched
in proportion those of the corresponding subtypes of RCC
[39 (63%) from kidneys harboring ccRCC, 9 (14%) from
pRCC, 6 (10%) from chRCC, and 8 (13%) from oncocy-
toma]. For all the target genes, methylation levels did not
differ significantly among normal tissue samples stratified
according with the paired renal cell tumor type. Moreover,
no statistically significant differences were found between
tumor and normal tissue samples concerning methylation
levels at the CDH1  and  PTGS2  promoters. However,
RASSF1A methylation levels were significantly higher in
pRCC than in normal tissue from all available cases (p =
0.002) and from kidneys harboring pRCC (p = 0.035).
After analyzing the methylation levels of the genes that
were differentially methylated among the four tumor sub-
types, empirical cutoff values were established to maxi-
mize the discriminative power of each gene (2.0 for
CDH1, 80.0 for PTGS2, and 230.0 for RASSF1A). Validity
estimates (sensitivity, specificity, positive and negative
predictive values) were calculated and are depicted in
Table 4.
Methylation profile and clinicopathologic parameters
Statistically significant associations between promoter
methylation levels and standard clinicopathologic param-
eters were only found for pRCC. Specifically, CDH1 and
RASSF1A  promoter hypermethylation levels were
inversely associated with tumor stage (p  = 0.031) and
nuclear grade (p = 0.022), respectively.
Discussion
In this study we attempted to define a set of methylation
markers that would allow for an accurate discrimination
among the four most common types or renal cell tumor
(ccRCC, pRCC, chRCC, and oncocytoma), as each type
displays dissimilar clinical behavior and successful pre-
operative cytological or histological assessment is
restricted. Through gene promoter methylation profiling
with QMSP, three genes were found to be differentially
methylated in the four tumor types. In particular, higher
CDH1  methylation levels were detected in ccRCC and
pRCC, whereas high RASSF1A  methylation levels were
associated with pRCC and high PTGS2 methylation levels
were characteristic of ccRCC. Remarkably, both chRCC
and oncocytomas displayed low methylation levels at
these three loci. Moreover, in pRCC, CDH1 and RASSF1A
methylation levels correlated negatively with tumor stage
and grade, respectively.
Overall, the frequency of promoter methylation found for
the majority of genes was somewhat different compared
with previous reports [16-20,30]. Differences in the
patient populations, as well as in the method used for
assessment of methylation, may account for these discrep-
ancies, as QMSP is generally more sensitive and specific
than conventional MSP, used in most of those earlier
studies [24]. It is noteworthy that most previous publica-
tions included no or just a few chRCC, so our tumor series
Table 3: Distribution of methylation levels of cancer-related genes in subtypes of renal cell carcinoma (RCC), oncocytoma, and 
morphologically normal renal tissue (NRT) [(target gene/ACTB) × 1000 expressed as median (interquartile range)]
Gene Clear cell RCC Papillary RCC Chromophobe RCC Oncocytoma p value* NRT
APC 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0-0)
ARHI 942.6 (634.7–1746.6) 807.2 (623.3–1322.6) 198.6 (148.7–1575.5) 930.1 (641.5–1654.5) ns 893.5 (574.2–1286.2)
CDH1 3.8 (0.5–12.3) 3.5 (0–19.3) 0 (0-0) 0 (0–1.1) 0.0007 2.3 (0.52–6.72)
CTNNB1 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0-0)
SFN 1441.4 (947.3–2592.1) 1048.2 (848.3–1354.5) 1192.4 (687.9–1477.4) 1302.5 (738.6–2591.6) ns 1088.4 (790.2–1497.1)
ARF/p14 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0–0.04)
CDKN2A/p16 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0-0)
RASSF1A 71.7 (4.7–265.5) 433.2 (236.4–966.0) 0 (0–2.7) 10.6 (2.2–27.5) 0.0001 59.6 (33.1–88.5)
GSTP1 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0-0)
MDR1 25.3 (10.5–58.2) 15.5 (6.0–23.7) 33.1 (2.6–54.9) 33.5 (7.9–117.9) ns 31.6 (16.6–41.9)
MTHFR 556.4 (236.9–965.9) 349.0 (181.6–561.9) 572.8 (340.3–887.0) 667.5 (634.4–1687.9) ns 419.7 (305.2–614.3)
PTGS2 72.9 (34.1–222.5) 17.7 (9.3–43.2) 6.0 (3.9–49.7) 16.2 (5.3–28.9) 0.002 54.6 (34.4–90.8)
TIMP3 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0-0)
ESR1 6.9 (0–31.3) 4.4 (2–10.9) 3.8 (0–19.1) 12.9 (7.7–76.5) ns 15.0 (0.9–35.5)
ESR2 0.6 (0–1.9) 0 (0–0.4) 0.3 (0–2.7) 0 (0–0.5) ns 0 (0–0.3)
FHIT 0.7 (0–5.6) 2.6 (0–47.0) 0.9 (0–4.0) 0.4 (0–6.6) ns 2.0 (0–17.7)
MGMT 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0-0)
RARβ2 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) ns 0 (0-0)
*Kruskall-Wallis one-way analysis of variance test among the four groups of renal cell tumors; IQR, interquartile range; ns, not significantBMC Cancer 2007, 7:133 http://www.biomedcentral.com/1471-2407/7/133
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is more representative of the spectrum of renal cell
tumors. Whereas we confirmed the high RASSF1A pro-
moter methylation levels in pRCC previously reported by
Gonzalgo and co-workers [17], we additionally found
that PTGS2 promoter methylation as a likely candidate
marker for ccRCC, something that might permit a more
accurate detection of this tumor type in limited tissue or
needle-aspirate samples.
An interesting finding of our study was the similar gene
methylation profile of chRCC and oncocytoma, which
has not been reported before to the best of our knowledge.
This might be unexpected owing to the malignant charac-
ter of the former and the benign behavior of the latter.
However, both chRCC and oncocytoma share their origin
from the distal nephron [31], a feature that might partially
explain the epigenetic similarity. Moreover, these two
tumor types might even look alike morphologically, as
the eosinophilic variant of chRCC constitutes a differen-
tial diagnosis of oncocytoma [4]. Although we observed a
tendency for higher RASSF1A  methylation levels in
chRCC than in oncocytomas, discriminating these two
tumor types using methylation markers remains a chal-
lenging task which needs to be addressed in future studies
in order to enable the critical distinction between a malig-
nant and a benign tumor.
Clinicopathologic correlates with methylation levels have
been previously reported by our research team in prostate
cancer [11,12]. However, in the present study the correla-
tions found for CDH1 and RASSF1A in pRCC are the in
opposite direction of those described in prostate carcino-
mas, as higher CDH1 and RASSF1A methylation levels
were associated with lower renal tumor stage and grade,
respectively. Because cytogenetic complexity is associated
with tumor progression in pRCC [4], the alternative
acquisition of promoter methylation at CDH1  and
RASSF1A  loci might characterize a different subset of
pRCC with less aggressive clinical behavior.
An important limitation of this study is the almost univer-
sal lack of statistically significant differences in methyla-
tion levels between morphologically normal and
neoplastic renal tissues, with the notable exception of
RASSF1A in pRCC. Gonzalgo and co-workers also found
relatively high levels of methylation in normal renal tis-
sue, collected from specimens harboring a renal neoplasm
[17]. Interestingly, no significant differences in methyla-
tion levels were found among normal tissues procured
from kidneys with different tumor types. Based on these
findings, we are tempted to speculate that, at least in some
cases, morphologically normal renal tissue might acquire
aberrant methylation (eventually age-related) at some
gene promoters owing to a "field-effect" phenomenon,
with additional epigenetic or cytogenetic alterations then
fostering tumor development. This hypothesis is consist-
ent with previous reports of specific detection of renal
malignancy in urine (in which normal renal epithelial
cells are shed) using similar panels of methylation mark-
ers [16,20]. However, considering the main purpose of
our study (i.e., the development of methylation markers
for detection and discrimination of renal cell neoplasms),
the similar levels of promoter methylation in normal and
neoplastic renal tissue constitutes a confounding variable
which needs clarification, requiring the analysis of normal
Methylation levels Figure 1
Methylation levels. Distribution of promoter methylation lev-
els [(target gene/ACTB) × 1000] of (A) CDH1, (B) PTGS2, and 
(C) RASSF1A in clear cell (ccRCC), papillary (pRCC), and 
chromophobe (chRCC) renal carcinomas, and oncocytomas.BMC Cancer 2007, 7:133 http://www.biomedcentral.com/1471-2407/7/133
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renal tissue from kidneys not harboring a neoplasm,
which we are currently collecting.
Conclusion
In conclusion, we found that a gene panel including
CDH1, PTGS2, and RASSF1A which might contribute to a
more accurate detection and discrimination of the com-
mon renal tumors. However, future studies addressing the
discrimination between chRCC and oncocytoma, as well
as the significance of aberrant methylation in morpholog-
ically normal renal tissue are required to allow the devel-




QMSP, quantitative methylation-specific PCR;
ccRCC, clear cell renal cell carcinoma;
pRCC, papillary renal cell carcinoma;
chRCC, chromophobe renal cell carcinoma;
CDH1, cadherin 1, type 1, E-cadherin (epithelial);
PTGS2, prostaglandin-endoperoxide synthase 2;
RASSF1A, Ras association domain family 1A;
RCC, renal cell carcinoma;
ACTB, beta actin;
NRT, normal renal tissue.
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